vs
BIOCRYST PHARMACEUTICALS INC（BCRX）与Shoals Technologies Group, Inc.（SHLS）财务数据对比。点击上方公司名可切换其他公司
BIOCRYST PHARMACEUTICALS INC的季度营收约是Shoals Technologies Group, Inc.的1.1倍（$156.4M vs $140.6M），Shoals Technologies Group, Inc.同比增速更快（74.9% vs 7.5%），过去两年BIOCRYST PHARMACEUTICALS INC的营收复合增速更高（19.6% vs 19.0%）
BioCryst Pharmaceuticals是一家总部位于美国北卡罗来纳州达勒姆的制药企业，属于后期发展阶段的生物科技公司，聚焦于治疗罕见重症的口服药物研发。其研发的抗病毒药物帕拉米韦（商品名Rapivab）于2014年12月获得美国FDA批准，此后也陆续在日本、韩国与中国获批上市。
Shoals科技集团是可再生能源及电动出行领域的电气系统平衡解决方案供应商，核心产品覆盖光伏、储能及充电桩用连接组件，主要服务北美、欧洲、亚太市场的公用事业、工商业及民用客户。
BCRX vs SHLS — 直观对比
营收规模更大
BCRX
是对方的1.1倍
$140.6M
营收增速更快
SHLS
高出67.4%
7.5%
两年增速更快
BCRX
近两年复合增速
19.0%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $156.4M | $140.6M |
| 净利润 | — | $-297.0K |
| 毛利率 | — | 29.2% |
| 营业利润率 | 13.6% | 5.5% |
| 净利率 | — | -0.2% |
| 营收同比 | 7.5% | 74.9% |
| 净利润同比 | — | -5.3% |
| 每股收益（稀释后） | $0.00 | $0.00 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCRXSHLS
| Q1 26 | $156.4M | $140.6M | ||
| Q4 25 | $406.6M | $148.3M | ||
| Q3 25 | $159.4M | $135.8M | ||
| Q2 25 | $163.4M | $110.8M | ||
| Q1 25 | $145.5M | $80.4M | ||
| Q4 24 | $131.5M | $107.0M | ||
| Q3 24 | $117.1M | $102.2M | ||
| Q2 24 | $109.3M | $99.2M |
净利润BCRXSHLS
| Q1 26 | — | $-297.0K | ||
| Q4 25 | $245.8M | $8.1M | ||
| Q3 25 | $12.9M | $11.9M | ||
| Q2 25 | $5.1M | $13.9M | ||
| Q1 25 | $32.0K | $-282.0K | ||
| Q4 24 | $-26.8M | $7.8M | ||
| Q3 24 | $-14.0M | $-267.0K | ||
| Q2 24 | $-12.7M | $11.8M |
毛利率BCRXSHLS
| Q1 26 | — | 29.2% | ||
| Q4 25 | 97.7% | 31.6% | ||
| Q3 25 | 98.6% | 37.0% | ||
| Q2 25 | 98.3% | 37.2% | ||
| Q1 25 | 96.9% | 35.0% | ||
| Q4 24 | 95.4% | 37.6% | ||
| Q3 24 | 97.3% | 24.8% | ||
| Q2 24 | 98.4% | 40.3% |
营业利润率BCRXSHLS
| Q1 26 | 13.6% | 5.5% | ||
| Q4 25 | 64.0% | 11.7% | ||
| Q3 25 | 18.6% | 13.7% | ||
| Q2 25 | 18.2% | 14.4% | ||
| Q1 25 | 14.6% | 5.4% | ||
| Q4 24 | -3.4% | 15.4% | ||
| Q3 24 | 6.6% | 4.4% | ||
| Q2 24 | 8.0% | 18.7% |
净利率BCRXSHLS
| Q1 26 | — | -0.2% | ||
| Q4 25 | 60.5% | 5.5% | ||
| Q3 25 | 8.1% | 8.7% | ||
| Q2 25 | 3.1% | 12.5% | ||
| Q1 25 | 0.0% | -0.4% | ||
| Q4 24 | -20.4% | 7.3% | ||
| Q3 24 | -12.0% | -0.3% | ||
| Q2 24 | -11.6% | 11.9% |
每股收益（稀释后）BCRXSHLS
| Q1 26 | $0.00 | $0.00 | ||
| Q4 25 | $1.13 | $0.05 | ||
| Q3 25 | $0.06 | $0.07 | ||
| Q2 25 | $0.02 | $0.08 | ||
| Q1 25 | $0.00 | $0.00 | ||
| Q4 24 | $-0.13 | $0.04 | ||
| Q3 24 | $-0.07 | $0.00 | ||
| Q2 24 | $-0.06 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $259.0M | $1.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $601.6M |
| 总资产 | $465.1M | $1.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BCRXSHLS
| Q1 26 | $259.0M | $1.9M | ||
| Q4 25 | $274.7M | $7.3M | ||
| Q3 25 | $212.9M | $8.6M | ||
| Q2 25 | $260.0M | $4.7M | ||
| Q1 25 | $295.1M | $35.6M | ||
| Q4 24 | $320.9M | $23.5M | ||
| Q3 24 | $96.8M | $11.1M | ||
| Q2 24 | $78.4M | $3.2M |
总债务BCRXSHLS
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $141.8M | ||
| Q4 24 | — | $141.8M | ||
| Q3 24 | — | $141.8M | ||
| Q2 24 | — | $146.8M |
股东权益BCRXSHLS
| Q1 26 | — | $601.6M | ||
| Q4 25 | $-119.2M | $600.0M | ||
| Q3 25 | $-387.9M | $589.6M | ||
| Q2 25 | $-421.6M | $575.4M | ||
| Q1 25 | $-451.9M | $558.9M | ||
| Q4 24 | $-475.9M | $556.8M | ||
| Q3 24 | $-468.6M | $545.2M | ||
| Q2 24 | $-475.6M | $544.6M |
总资产BCRXSHLS
| Q1 26 | $465.1M | $1.0B | ||
| Q4 25 | $514.2M | $904.1M | ||
| Q3 25 | $446.4M | $851.8M | ||
| Q2 25 | $457.2M | $795.0M | ||
| Q1 25 | $480.0M | $788.4M | ||
| Q4 24 | $490.4M | $793.1M | ||
| Q3 24 | $491.3M | $801.3M | ||
| Q2 24 | $472.4M | $788.4M |
负债/权益比BCRXSHLS
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.25× | ||
| Q4 24 | — | 0.25× | ||
| Q3 24 | — | 0.26× | ||
| Q2 24 | — | 0.27× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCRX
| ORLADEYO | $148.3M | 95% |
| Other revenues | $5.0M | 3% |
| License revenue | $3.0M | 2% |
SHLS
暂无分部数据
